Shares of Replimune Group Inc. (REPL) surged 5.71% in pre-market trading on Friday, following the company's announcement of a mixed shelf filing for up to $250 million. The significant price movement reflects investors' positive reaction to the potential capital raising initiative.

According to a SEC filing, Replimune Group has submitted a mixed shelf registration, allowing the company to issue various types of securities, including common stock, preferred stock, debt securities, warrants, or units, up to an aggregate amount of $250 million. This strategic move provides the company with increased financial flexibility and the ability to capitalize on market opportunities as they arise.

Replimune Group, a clinical-stage biotechnology company focused on developing novel oncolytic immunotherapies, could use the potential funds to advance its pipeline of cancer treatments, expand research and development efforts, or strengthen its overall financial position. The market's enthusiastic response suggests that investors view this financial maneuver as a positive step for the company's growth prospects and long-term value creation.